Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoTriColor: Galunisertib and Capecitabine in TGF-beta Activated CRC
NCT03470350Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2018
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
A Phase 2 trial of galunisertib in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Planned start Aug 2018; status: withdrawn.
02
Drugs
galunisertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03470350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03470350.